MedPath

Metabolic Effects of Non-nutritive Sweeteners

Not Applicable
Completed
Conditions
Obesity
Interventions
Dietary Supplement: Sucralose
Other: Water
Dietary Supplement: glucose load
Registration Number
NCT02413424
Lead Sponsor
University of Illinois at Urbana-Champaign
Brief Summary

The purpose of this research study is to examine whether sugar-replacement sweeteners that are currently on the market (ex. Sucralose, which is in Splenda) change how well the body works to control blood sugar.

Detailed Description

The investigators of this study have recently found that sucralose, the most commonly used non-nutritive sweetener (NNS), affects the glycemic response to an oral glucose tolerance test (OGTT) and potentiates glucose-stimulated insulin secretion in obese people who are not regular consumers of NNS. However, studies conducted in healthy lean adults, none of which control for previous use of NNS, show that sucralose does not affect glycemic or hormonal responses to the ingestion of glucose or other carbohydrates. Therefore, we do not know a) whether sucralose effects are limited to obese subjects, or are generalizable to lean people when controlling for prior history of NNS consumption, and b) mechanism(s) responsible for the acute effect of sucralose on glucose metabolism as we measured in obese subjects. The aim of this study is to determine the effects of an acute intake of sucralose on the metabolic response to an oral glucose tolerance test in lean and obese people.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria
  • BMI ≥ 30 kg/m2 or BMI ≥ 18 kg/m2 and BMI<25 kg/m2
  • "insulin sensitive": based on the homeostasis model assessment of insulin resistance (HOMA-IR) <3
Exclusion Criteria
  • BMI ≥ 25 kg/m2 and BMI<30 kg/m2
  • HOMA-IR>3
  • Current smoker or quit smoking less than 6 months ago
  • pregnancy or breastfeeding
  • subjects who have malabsorptive syndromes, phenylketonuria, inflammatory intestinal disease, liver or kidney diseases, diabetes
  • subjects who are taking any medication that might affect metabolism
  • anemia
  • regular use of non-nutritive sweeteners

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Drink SucraloseSucraloseSubjects will drink sucralose 10 min before drinking a glucose load
Drink Waterglucose loadSubjects will drink water 10 min before drinking a glucose load
Taste and spit SucraloseSucraloseSubjects will taste and spit up sucralose 10 min before drinking a glucose load
Drink WaterWaterSubjects will drink water 10 min before drinking a glucose load
Taste and spit Sucraloseglucose loadSubjects will taste and spit up sucralose 10 min before drinking a glucose load
Drink Sucraloseglucose loadSubjects will drink sucralose 10 min before drinking a glucose load
Primary Outcome Measures
NameTimeMethod
Glucose rate of appearanceup to 5 hours after drinking a glucose load

Blood samples will be collected before and for 5 hours after drinking a glucose load to determine glucose and glucose tracer:tracee ratios.

Peak insulin secretion rateup to 5 hours after drinking a glucose load

Blood samples will be collected before and for 5 hours after drinking a glucose load to determine plasma insulin and C-peptide. Insulin secretion rate will be assessed using the minimal model of Breda and collaborators.

Secondary Outcome Measures
NameTimeMethod
Glucose-dependent insulinotropic polypeptide (GIP)up to 5 hours after drinking a glucose load

Blood samples will be collected before and for 5 hours after drinking a glucose load to determine GIP.

Sucralose concentrations in plasmaup to 310 min after drinking the sucralose load

Sucralose concentrations in plasma will be measured by using liquid chromatography-mass spectrometry.

Trial Locations

Locations (1)

University of Illinois at Urbana Champaign

🇺🇸

Urbana, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath